A combined evaluation incorporating the Th1 and Th2 scores, expression levels of genes involved in the PD-L1/PD-1 axis, and the 14 novel candidate genes involved in Th1 and Th2 responses, NF-κB signaling, and IL6/STAT3 signaling could be used to derive more accurate estimates of the prognoses of GBM patients. This evidence concerns the gene CD274 and glioblastoma.